Adaptimmune Therapeutics (FRA:473A) ROCE % : 131.49% (As of Jun. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Adaptimmune Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Adaptimmune Therapeutics's annualized ROCE % for the quarter that ended in Jun. 2024 was 131.49%.

Adaptimmune Therapeutics ROCE % Historical Data

The historical data trend for Adaptimmune Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptimmune Therapeutics ROCE % Chart

Adaptimmune Therapeutics Annual Data

Trend

Jun14

Jun15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-71.02

-46.54

-41.09

-50.05

-57.27

Adaptimmune Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
ROCE %	Get a 7-Day Free Trial															-33.54	-77.02	-91.45	-98.34	131.49

Adaptimmune Therapeutics ROCE % Calculation

Adaptimmune Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-126.581	/	( ( (310.497 - 60.889)	+	(259.159 - 66.747) )	/ 2 )
	=	-126.581	/	( (249.608	+	192.412)	/ 2 )
	=	-126.581	/	221.01
	=	-57.27 %

Adaptimmune Therapeutics's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Mar. 2024 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Mar. 2024 )		(Q: Jun. 2024 )
	=	262.248	/	( ( (237.369 - 61.098)	+	(298.861 - 76.246) )	/ 2 )
	=	262.248	/	( ( 176.271	+	222.615 )	/ 2 )
	=	262.248	/	199.443
	=	131.49 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

Adaptimmune Therapeutics (FRA:473A) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Adaptimmune Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Adaptimmune Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptimmune Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptimmune Therapeutics PLC (FRA:473A) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ADAP:USA 473A:Germany

Address

60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY

Website

https://www.adaptimmune.com

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.

Adaptimmune Therapeutics Headlines

No Headlines